BCL2 and myeloid leukemia: Downregulation of miR-16 enhances cell proliferation through AKT3 kinase (RAC-gamma serine/threonine-protein kinase), MAP (mitogen-activated protein) kinases, ribosomal protein S6, and NF-κB (nuclear factor-κB) activator MAP3KIP3 inhibition, and influences angiogenesis and apoptosis by increasing the expression of VEGF (vascular endothelial growth factor), BCL2 (B cell Lymphoma 2) proteins, Cyclin D1 (CCND1), WNT3A (Wnt family member 3A), and MCL1 (induced myeloid leukemia cell differentiation) genes [13].